Ravi K Goyal
Overview
Explore the profile of Ravi K Goyal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hillmen P, Xie J, Yong A, Waweru C, Sorof T, Goyal R, et al.
EJHaem
. 2022 Jul;
2(2):219-227.
PMID: 35845284
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute...
12.
Ardeshirrouhanifard S, An H, Goyal R, Raji M, Segal J, Alexander G, et al.
Pharmacotherapy
. 2022 Apr;
42(5):375-386.
PMID: 35364622
Background: Anticoagulation among patients with cancer and atrial fibrillation is challenging due to elevated risk of bleeding and stroke. We characterized use of oral anticoagulants among patients with cancer and...
13.
Goyal R, Jain P, Nagar S, Le H, Kabadi S, Davis K, et al.
Leuk Lymphoma
. 2021 May;
62(6):1325-1334.
PMID: 33966583
Most data on overall survival (OS) and adverse events (AEs) in patients with mantle cell lymphoma (MCL) are from controlled trials; therefore, in this population-based study, we retrospectively assessed treatment...
14.
Goyal R, Nagar S, Kabadi S, Le H, Davis K, Kaye J
Cancer Med
. 2021 Mar;
10(8):2690-2702.
PMID: 33734606
Background: Information on overall survival (OS) and adverse events (AEs) in patients with chronic lymphocytic leukemia (CLL) is mostly available from clinical trials. We therefore conducted a population-based retrospective cohort...
15.
Goyal R, Cuyun Carter G, Nagar S, Smyth E, Price G, Parikh R, et al.
Expert Rev Pharmacoecon Outcomes Res
. 2020 Aug;
21(4):699-710.
PMID: 32755262
Background: Real-world evidence specific to HR+/HER2- metastatic breast cancer (MBC) prior to introduction of CDK4/6 inhibitors is limited. In an effort to provide context for the introduction of new treatments,...
16.
Kabadi S, Goyal R, Nagar S, Kaye J, Davis K
Cancer Med
. 2019 May;
8(8):3803-3810.
PMID: 31144473
Introduction: Contemporary data describing treatment patterns, adverse events (AEs), and outcomes in patients with chronic lymphocytic leukemia (CLL) in clinical practice are lacking. We conducted a retrospective cohort study and...
17.
Goyal R, Cuyun Carter G, Nagar S, Smyth E, Price G, Huang Y, et al.
Curr Med Res Opin
. 2019 May;
35(10):1699-1710.
PMID: 31060392
Endocrine therapy (ET) remains a foundation of systemic therapy for HR+/ HER2- metastatic breast cancer (MBC), although chemotherapy (CT) is used in select patients. In this "real-world" study, we explored...
18.
Goyal R, Nagar S, Kabadi S, Kaye J, Seal B, Mato A
Leuk Lymphoma
. 2018 Oct;
60(4):955-963.
PMID: 30277099
In view of recent therapeutic advances in mantle cell lymphoma (MCL), the aim of this retrospective cohort analysis was to assess treatment patterns, adverse events (AEs), resource utilization, and health...
19.
Goyal R, Tzivelekis S, Rothman K, Candrilli S, Kaye J
Support Care Cancer
. 2017 Sep;
26(2):539-548.
PMID: 28921379
Purpose: The purpose of this study is to assess temporal trends in the use of granulocyte colony-stimulating factor (G-CSF) prophylaxis and risk of febrile neutropenia (FN) among older women receiving...
20.
Hillemeier M, Domino M, Wells R, Goyal R, Kum H, Cilenti D, et al.
Health Serv Res
. 2017 Jul;
53(4):2368-2383.
PMID: 28726272
Objective: To examine effects of maternity care coordination (MCC) on perinatal health care utilization among low-income women. Data Sources: North Carolina Center for Health Statistics Baby Love files that include...